

Table S3: Participant characteristic details

	Control (n = 88)	Intervention (n = 81)
Demographics		
Study site (%)		
Philadelphia (%)	16 (18.2)	15 (18.5)
Cincinnati (%)	12 (13.6)	14 (17.3)
Seattle (%)	16 (18.2)	13 (16.1)
St. Louis (%)	12 (13.6)	12 (14.8)
Montreal- McGill (%)	8 (9.1)	8 (9.9)
Montreal- Ste. Justine (%)	5 (5.7)	3 (3.7)
Toronto (%)	11 (12.5)	9 (11.1)
Vancouver (%)	8 (9.1)	7 (8.6)
Primary caregiver		
Mother	71 (80.7)	66 (81.5)
Father	11 (12.5)	9 (11.1)
Grandparent	2 (2.3)	1 (1.2)
Self	4 (4.6)	5 (6.2)
Education of primary caregiver		
Less than high school	5 (5.7)	9 (11.1)
High school	19 (21.6)	24 (29.6)
Some college	18 (20.5)	15 (18.5)
Completed Business/Trade/Technical School	5 (5.7)	2 (2.5)
College graduate	31 (35.2)	25 (30.9)
Completed Graduate School	10 (11.4)	6 (7.4)
Adults in household (number, not including pt)		
0	3 (3.4)	2 (2.5)
1	17 (19.3)	15 (18.5)
2	46 (52.3)	44 (54.3)
≥3	22 (25.0)	20 (24.7)
Treatment characteristics:		
Immunosuppressive medications		
Number taking twice per day tacrolimus (%)	62 (70.5)	61 (75.3)
Number taking once per day tacrolimus (%)	9 (10.2)	6 (7.4)
Number taking mycophenolate (%)	68 (77.3)	68 (84.0)
Number taking prednisone (%)	50 (56.8)	59 (72.8)
Number taking sirolimus (%)	16 (18.2)	17 (21.0)
Number taking cyclosporine (%)	2 (2.3)	2 (2.5)
Number taking azathioprine (%)	7 (8.0)	4 (4.9)
Number taking other (%)	6 (6.7)	1 (1.2)
Total number of doses per day (all meds)		
1	3 (3.4)	1 (1.2)
2	74 (84.1)	76 (93.8)
3	8 (9.1)	3 (3.7)
4	3 (3.4)	1 (1.2)
Median proportion of visits at which a caregiver was present (IQR)	100 (68-100)	100 (60-100)